Large Volume Wearable Injectors Market Size, Share, Trends, Industry Analysis Report

Market Outlook

The global large volume wearable injectors market, valued at USD 12.6 billion in 2025, is projected to reach USD 16.4 billion in 2026 and USD 31.4 billion by 2035, representing a CAGR of 7.5% during the forecast period 2026 to 2035. The market numbers have been calculated by taking into account the revenues generated through sales of large volume wearable injectors and related drug-device combination products.

To learn more about this report, request a free sample copy

Market Report: Key Takeaways

Market Size & Trends

• In terms of type of device, currently, the patch pumps hold the largest share (more than 90%) of the market.
• By usability, disposable devices dominate the current market by capturing ~90% of the market revenue and are expected to sustain this market dominance through 2035.
• Based on market share distribution by therapeutic area, devices used to treat autoimmune diseases are expected to drive the large volume wearable injectors market growth through 2035.
• In terms of geographical regions, North America holds the largest share, accounting for nearly 55% of the market.

Key Market Statistics

• Market Size in 2026: $16.4 Billion
• Estimated Market Size in 2035: $31.4 Billion
• CAGR (2026-2035): 7.5%
• North America: Largest market in 2026
• Asia: Fastest growing region

Market Introduction

The rising prevalence of chronic diseases, including cancer, autoimmune disorders, cardiovascular diseases, rare genetic conditions, and immunological disorders, continues to place pressure on healthcare systems worldwide. Many biologics used to treat these disorders require the administration of large volumes and highly viscous formulations. Traditionally, healthcare providers have delivered such therapies through intravenous infusions in hospitals and specialty clinics. However, the growing emphasis on home-based care and improved patient convenience has accelerated the need for alternative drug delivery approaches that support self-administration.

Large volume wearable injectors have emerged as an effective solution for the subcutaneous delivery of drug volumes exceeding 3 mL. These on-body devices administer high-volume biologics over an extended period, reducing the burden associated with frequent injections and infusion-based treatments. Further, they improve patient comfort, simplify drug administration, and support treatment adherence. As a result, device developers / manufacturers are increasingly exploring wearable injector technologies to enable the transition of several therapies from intravenous to subcutaneous administration. Device developers are also incorporating advanced features such as connectivity solutions, adherence monitoring, delivery status notifications, and digital health integration to enhance the patient experience.

Overall, with continued innovation in biologic drug development and increasing adoption of home-based treatment models, the demand for large volume wearable injectors is likely to grow significantly in the coming years.

What are the Key Commercialized Large Volume Wearable Injectors?

The large volume wearable injectors market comprises more than 20 pipeline products; of these, over five advanced drug delivery platforms have already been commercialized. These systems vary in terms of delivery mechanism, injection duration, and device design, enabling pharmaceutical companies to address diverse therapeutic requirements. Leading device developers have focused on improving patient convenience and dosing accuracy, resulting in the launch of several commercially available wearable injector devices. Some of these injectors are mentioned below:

Market Segmentation

Based on the research, we have segmented the large volume wearable injectors into type of device, usability, therapeutic area, and geographical regions.

By Type of Device

• Patch Pumps
• Infusion Pumps

By Usability

• Disposable
• Reusable (Disposable Components)

By Therapeutic Area

• Oncological Disorders
• Cardiovascular Disorders
• Autoimmune Disorders
• Neurological Disorders
• Other Disorders

By Geographical Regions

• North America
  • US
  • Canada
  • Mexico
• Europe
  • France
  • Germany
  • UK
  • Italy
  • Spain
  • Rest of Europe
• Asia
  • China
  • India
  • Japan
  • Pakistan
  • Rest of Asia
• Middle East and North Africa
  • Egypt
  • Israel
  • Saudi Arabia
• Latin America
  • Argentina
  • Brazil

Large Volume Wearable Injectors Market Key Insights

What Factors are Driving Increased Adoption of Large-Volume Drug Delivery Devices?

• Growing Adoption of High-Volume Biologic Therapies: The increasing use of biologics, including monoclonal antibodies, immunotherapies, and enzyme replacement therapies, is driving demand for such injectors. Many of these therapies require the administration of volumes exceeding the limits of conventional prefilled syringes and autoinjectors. Large volume wearable injectors enable the safe and convenient subcutaneous delivery of such therapies, making them an attractive option for both healthcare companies and patients.
• Need to Reduce Dependence on Infusion Centers: The growing burden on hospitals and infusion clinics has increased interest in alternative drug administration methods. These on-body large volume injectors allow patients to receive complex biologic therapies at home, reducing the need for lengthy infusion sessions and frequent hospital visits. This shift helps optimize healthcare resources while improving patient access to treatment. In addition, the convenience of self-administration, reduced treatment burden, and greater flexibility contribute to improved patient adherence and long-term treatment compliance, particularly for chronic diseases requiring repeated dosing. These clinical and patient-centric benefits are likely to strengthen the commercial adoption of large-volume drug delivery devices, encouraging pharmaceutical companies to incorporate them into combination products.

What are the Main Challenges Restraining the Growth of the Large Volume Wearable Injectors Market?

• High Development and Manufacturing Costs: Wearable injectors incorporate sophisticated components, including pumping systems, electronic controls, sensors, and connectivity features. The integration of these technologies increases development, manufacturing, and quality assurance costs. In addition, manufacturers must invest in specialized production infrastructure, component validation, and rigorous testing to ensure consistent device performance and reliability, resulting in higher production costs and pressure on profit margins.
• Evolving Regulatory Environment: Large volume wearable infusors are often developed as drug-device combination products, requiring compliance with both pharmaceutical and medical device regulations. Demonstrating device reliability, safety, usability, and compatibility with specific drug formulations can lengthen development timelines and increase regulatory burden for manufacturers.

Growing Shift from IV to Subcutaneous Drug Delivery

The transition from intravenous (IV) infusion to subcutaneous (SC) drug delivery for large volume wearable devices is emerging as one of the most significant trends shaping the biologics and oncology treatment landscape. Advances in high-concentration formulations, recombinant hyaluronidase technologies, and large-volume wearable injectors have enabled the administration of therapies that were previously restricted to infusion centers through a more convenient SC route. This shift is driven by the need to improve patient experience, reduce treatment duration, alleviate pressure on healthcare infrastructure, and lower overall healthcare costs while maintaining comparable efficacy and safety profiles.

Wearable on-body delivery systems (OBDS) are further accelerating this transition by enabling hands-free administration of larger drug volumes in outpatient and home-care settings, thereby expanding access to complex biologics. Recent clinical evidence, including studies evaluating subcutaneous isatuximab delivered via an on-body injector, highlights the potential of these technologies to streamline clinical workflows, reduce healthcare professional burden, and support patient-centric care models across chronic diseases and oncology indications.

Recent Developments

• In June 2026, the European Commission approved the subcutaneous formulation of Sarclisa, making it the first anticancer therapy in the EU to be administered via an on-body injector (OBI), enabling more convenient treatment in outpatient and home settings.
• In January 2026, Becton Dickinson presented its drug delivery innovations at Pharmapack 2026, showcasing technologies designed to support the evolving needs of biologics and patient-centric healthcare.
• In October 2025, Enable Injections and Incyte signed a technology licensing agreement to support the at-home administration of Incyte's investigational cancer therapy using Enable's enFuse® wearable injector.

Industry Experts on Large Volume Wearable Injectors

The large volume wearable injectors market is poised for transformative growth and will continue to evolve rapidly over the coming years. Validating this gradual shift in wearable injector's technology landscape, Michael D. Hooven (CEO of Enable Injections), stated that, "By continuing to collaborate closely with our pharmaceutical partners, we remain steadfast in our mission to improve the lives of patients and caregivers through our wearable enFuse technology, minimizing disruption to their daily lives"

Discussions with multiple stakeholders in this domain influenced the opinions and insights presented in this study. The market report includes transcripts of the following other third-party discussions:

• Former President and Chief Executive Officer, Mid-sized Company, US
• Chief Executive Officer, Mid-sized Company, US
• Chief Executive Officer, Small Company, US
• Chief Executive Officer, Small Company, Denmark
• Former Vice President and General Manager, Biologics, Very Large Company, US
• Vice President of Combination Product Development, Small Company, US
• Vice President and Chief Scientist, Large Company, Israel
• Vice President, Marketing and Alliance Management, Mid-sized Company, US
• Engineering Project Manager / Senior System Engineer, Small Company, Switzerland
• Anonymous, Large Company, Switzerland

Market Share Insights

Which Type of Device Accounts for the Largest Share?

Based on type of device, the market is divided into patch pumps and infusion pumps.

According to our estimates, the patch pumps / injectors segment accounts for nearly 90% of the current market share. This is due to the growing shift toward decentralized healthcare; wherein wearable patch injectors enable the safe and convenient administration of high-volume biologics in home settings. These devices reduce dependence on infusion centers, improve patient adherence and comfort, optimize healthcare resource utilization, and support the broader industry trend toward self-administered therapies.

On the other hand, the infusion pumps / injectors segment is likely to witness a higher CAGR in the future. This growth is driven by advancements in smart infusion technologies, rising demand for home-based infusion services, and the expansion of outpatient care models. This has accelerated the uptake of infusion pumps, particularly for therapies requiring prolonged administration and enhanced clinical oversight. For instance, in June 2026, Eitan Medical partnered with WeInfuse to integrate connected smart infusion pumps with digital clinical workflow platforms. This partnership enables remote monitoring, automated documentation, and improved infusion management across ambulatory and home care settings.

Regional Analysis: Which Regions are Showing the Fastest Growth in the Large Volume Wearable Injectors Market?

North America: Dominating the Market by Securing Highest Share

North America accounts for nearly 55% of the market share. The strong presence of leading pharmaceutical and medical device companies, widespread adoption of innovative drug delivery technologies, and favorable reimbursement policies continue to drive market growth across the region. Recent FDA guidance has further clarified expectations for human factors validation, usability engineering, and risk-based documentation in medical device submissions, encouraging manufacturers to incorporate these requirements earlier in product development. For device developers, demonstrating device reliability, drug-device compatibility, and safe self-administration has become increasingly important for regulatory approval, thereby supporting the successful commercialization of these wearable injectors.

Asia: An Emerging Growth Spot

In Asia, the market is likely to grow at a relatively faster pace (CAGR of 9.7%), through 2035. This is due to its large patient population, rising burden of chronic diseases, improving healthcare infrastructure, and rapid expansion of the biopharmaceutical industry. Additionally, growing adoption of home healthcare solutions and supportive government initiatives aimed at strengthening healthcare delivery and medical technology innovation are expected to further accelerate market growth in the region.

Which Type of Device Leads the Large Volume Wearable Injectors Market?

On the basis of usability, the global market is divided into disposable and reusable (disposable components) types of devices.

Our large volume wearable injectors market analysis estimates indicate that the disposable devices segment holds the largest share in the current market, due to several operational, clinical, and economic advantages. These devices eliminate the need for cleaning, maintenance, and reprocessing, thereby reducing the risk of contamination and medication administration errors.

However, the reusable devices with disposable components are likely to grow at a higher CAGR during the forecast period. This is due to the increasing demand for cost-effective and sustainable drug delivery solutions. Unlike fully disposable systems, these systems reuse the primary electronic or mechanical unit while replacing only the patient-contact and drug-containing components, thereby reducing treatment costs and medical waste.

Which Therapeutic Area will dominate the Large Volume Wearable Injectors Market?

Based on the therapeutic area, the global market is sub-segmented across oncological disorders, cardiovascular disorders, neurological disorders, autoimmune disorders, and other disorders.

According to our analysis, the autoimmune disorders segment dominates the ultra-large volume wearable injectors market, owing to the high prevalence of conditions such as rheumatoid arthritis, psoriasis, multiple sclerosis, inflammatory bowel disease, and systemic lupus erythematosus. The growing use of biologics and other targeted therapies for the long-term management of these diseases has increased demand for advanced drug delivery solutions. Market growth is further supported by favorable reimbursement policies for self-administered biologics across several developed healthcare markets, where payers increasingly encourage treatment in home settings. This helps to reduce the costs associated with hospital or infusion center-based care. Consequently, pharmaceutical manufacturers are prioritizing the development of subcutaneous drug-device combination products, including wearable injectors, to improve patient convenience while demonstrating economic value to both payers and healthcare providers.

Scope of Large Volume Wearable Injectors Market Report

Frequently Asked Questions

Question 1: What is a large volume wearable injector?

Answer: A large volume wearable injector is an on-body drug delivery device designed to administer large volumes of therapeutic agents, typically exceeding 3 mL, through the subcutaneous route.

Question 2: How big is the large volume wearable injectors market?

Answer: The current market for ultra-large volume injectors is valued at USD 16.4 billion.

Question 3: What is the outlook for large volume wearable injectors?

Answer: The global market is likely to reach USD 31.4 billion in 2035.

Question 4: What is the large volume wearable injectors market growth rate till 2035?

Answer: The market for large volume wearable injectors is poised to grow at a steady pace (CAGR of 7.5%) through 2035.

Question 5: Which region holds the largest market share?

Answer: North America holds the majority of the large volume wearable injectors share (nearly 55%).

Question 6: Who are the key players providing on-body injectors?

Answer: Key players are Becton Dickinson (BD), Enable Injections, E3D Elcam Drug Delivery Devices, Stevanato Group, and Ypsomed.